Insmed reports positive 12-month data for TPIP in PAH study.
Insmed announced sustained efficacy and safety for once-daily TPIP, strengthening the potential for the drug to become the prostanoid of choice for PAH patients. These data advance the company's clinical development pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day